APG Asset Management N.V. Buys 88,707 Shares of IQVIA Holdings Inc. (NYSE:IQV)

APG Asset Management N.V. grew its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 516.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 105,871 shares of the medical research company's stock after acquiring an additional 88,707 shares during the period. APG Asset Management N.V. owned 0.06% of IQVIA worth $20,091,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Pine Valley Investments Ltd Liability Co increased its position in IQVIA by 0.5% during the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company's stock worth $2,247,000 after buying an additional 50 shares during the last quarter. Howard Capital Management Inc. increased its holdings in shares of IQVIA by 4.9% during the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock valued at $225,000 after acquiring an additional 54 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in IQVIA by 1.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company's stock worth $1,068,000 after purchasing an additional 56 shares during the last quarter. Cypress Wealth Services LLC boosted its position in IQVIA by 4.8% during the fourth quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company's stock worth $244,000 after purchasing an additional 57 shares during the period. Finally, Harbor Investment Advisory LLC grew its holdings in IQVIA by 4.7% during the fourth quarter. Harbor Investment Advisory LLC now owns 1,286 shares of the medical research company's stock valued at $253,000 after purchasing an additional 58 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on IQV shares. Morgan Stanley boosted their price objective on shares of IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 11th. Barclays reaffirmed an "equal weight" rating and issued a $170.00 price target (down from $235.00) on shares of IQVIA in a research report on Thursday, April 10th. Truist Financial cut their price objective on IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research report on Thursday, April 10th. UBS Group lowered their target price on IQVIA from $260.00 to $255.00 and set a "buy" rating on the stock in a report on Friday, February 7th. Finally, Stifel Nicolaus cut their price target on IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a report on Friday, February 7th. Six research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, IQVIA has a consensus rating of "Moderate Buy" and a consensus target price of $241.50.

IQVIA Price Performance

Shares of IQV traded down $2.36 during trading hours on Tuesday, hitting $148.56. The stock had a trading volume of 332,208 shares, compared to its average volume of 1,384,415. IQVIA Holdings Inc. has a 52 week low of $135.97 and a 52 week high of $252.88. The stock has a market capitalization of $26.19 billion, a price-to-earnings ratio of 19.81, a P/E/G ratio of 1.99 and a beta of 1.46. The company's fifty day moving average is $181.23 and its two-hundred day moving average is $198.80. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.